Business intelligence
for the Lab Diagnostics industry
Already a Subscriber? Log in Here
We offer four monthly reports, each focused on the industry from a unique angle, covering science & technology, compliance, business, and legislation & regulations.
Diagnostic Testing & Emerging Technologies
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Lab Compliance Advisor
Offers practical, “what-to-do” and “how-to-do-it” help to comply with the latest state and federal laws, rules, and regulations that affect your diagnostic lab or pathology practice
Laboratory Industry Report
Keeps you up-to-date on lab business and competitive strategy, market trends and opportunities, and M&A and investment activity in today’s diagnostic lab industry
National Lab Reporter
Keeps you up-to-date on federal and state laws, regulations, new legislation, and court cases that affect your diagnostic lab or pathology practice
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
Weekly Enforcement Report: Drug Testing Fraud Dominates
Last week’s three key cases included two involving drug testing that was either medically unnecessary, or not provided at all.
Proposed Rule Would Water Down CLIA Requirements for Lab Directors and Testing Personnel
While the rule has not yet been approved, if it is, nursing degrees would be considered the equivalent of biological science degrees.
Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
Proposed FTC Ban on Noncompete Agreements Could Be Highly Disruptive to Lab Staffing
A proposed move to make noncompete agreements illegal could impact retention of some laboratory employees.
Weekly Enforcement Report: Drug Testing Fraud Dominates
Last week’s three key cases included two involving drug testing that was either medically unnecessary, or not provided at all.
Brief Your Billing & Coding Staff on New Medicare HCPCS & CLIA Code Changes
To avoid claims denials and improper billings, ensure billing and coding staff is aware of, and has adjusted to, all recent coding changes.
Compliance Alert: 8 New Medicare COVID-19 Test Payment Rules Take Effect on May 12
CMS recently issued long-awaited guidance on post-PHE changes to Medicare coverage of SARS-CoV-2 diagnostic tests.
Proposed Rule Would Water Down CLIA Requirements for Lab Directors and Testing Personnel
While the rule has not yet been approved, if it is, nursing degrees would be considered the equivalent of biological science degrees.
Staffing Special Report: CMS Proposes Changes to CLIA Laboratory Personnel Requirements
An overview and analysis of the recently proposed changes and how they could affect your medical laboratory.
Reimbursement: ABN’s Failure to Include List Prices for Denied Lab Tests Is Not Consumer Fraud
Recent case shows why failing to disclose to individuals the lab test list prices they may need to pay doesn’t count as consumer fraud.
Thriving in a Difficult Economy: Patient-centric Strategies That Will Improve Your Bottom Line
Learn how your lab can effectively respond in these uncertain economic times to strengthen your competitive advantage and your bottom line.
Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
Convicted Lab Owner Fails to Report to Prison
In addition to the usual FCA-related fare, an arrest warrant was issued for a convicted lab co-owner after he failed to show up for prison.
